News & Trends - Biotechnology

$41.7 million funding to commercialise novel therapies

Health Industry Hub | November 23, 2020 |
[Total: 1    Average: 5/5]

Biotech News: An innovative nasal treatment to combat COVID-19, common colds and flu is being taken to the next stage of research.

Developed by Australian biotech company Ena Respiratory, INNA-051 works by stimulating the innate immune system, the first line of defence against the invasion of pathogens into the body.

The Government, alongside Brandon Capital Partners has committed $11.7 million to test the nasal spray treatment that targets the primary site of most respiratory virus infections, including SARS-CoV-2, the strain of coronavirus that causes COVID-19, and influenza.

The program has been designed so that if successful, INNA-051 will be manufactured and formulated in Australia, creating manufacturing jobs into the future.

You may also like ARCS Australia announces new Board Directors and Life Members

In addition, four further projects will also share in almost $30 million to commercialise their ideas.

Minister for Health Greg Hunt said “Australia’s health and medical researchers are world class and this investment will continue the proud Australian tradition of discovery and translation that saves lives and improves lives. The Morrison Government is backing Australia’s next generation of medical advances and this investment means these businesses have the potential to take their technology to the next level.”

Minister for Industry, Science and Technology Karen Andrews said “The Biomedical Translation Fund fosters potential breakthroughs that will not only improve people’s lives, but also help Australian companies create more jobs and grow into new markets.

“The Morrison Government is looking to develop our manufacturing capacity in medical products and this fund is yet another way we can help commercialise great Australian ideas right here at home,” she said.

Funding consists of equal parts Commonwealth and private sector funding and is operated by three private sector fund managers: Brandon Capital Partners, OneVentures Healthcare Fund and BioScience Managers.

The other four investments made through the Fund are:

  1. OneVentures Healthcare Fund has committed $9.5 million to Kira Biotech. Kira Biotech is researching treatments for autoimmune disease, a condition where the immune system attacks healthy cells or the body’s organs. Kira Biotech’s research directs components of the body’s normal immune response to the impaired cells of a person suffering from an autoimmune disease, allowing the immune system to work properly.
  2. BioScience Managers has committed $10 million to medical device company Closed Loop Medical. Closed Loop Medical’s technology aims to improve treatments for conditions of the body’s nervous system. The technology being developed will record and measure a person’s unique response to stimulation and provide a tailored outcome for the patient. The technology has the potential to be applied to disorders including Parkinson’s disease, epilepsy and bladder dysfunction.
  3. BioScience Managers has also committed $5 million to Adherium. Adherium is developing a digital medication monitoring system for people with respiratory diseases. The monitoring system will initially help people with conditions like asthma, by tracking their drug usage and issuing reminders to ensure they take their medication.
  4. Brandon Capital Partners’ MRCF BTF Fund has invested more than $5 million in Polyactiva. Polyactiva’s novel polymer technology delivers medication to the eyes. Its lead product will be used for treating glaucoma, the leading cause of blindness affecting 70 million people globally. Polyactiva’s novel delivery technology will provide six months of therapy from a single treatment, overcoming many of the challenges of delivering medication with eye drops.

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Pharmaceuticals

Pharma News - Novel gene therapy in advanced bowel cancer

Novel gene therapy in advanced bowel cancer

Health Industry Hub | November 27, 2020 |

Pharma News: For the first time, SAHMRI and University of Adelaide researchers are investigating gene therapy as an option to […]


Best Practice

Best Practice Pharma Biotech Medtech -Search for meaning more fulfilling than the pursuit of personal happiness

Search for meaning more fulfilling than the pursuit of personal happiness

Health Industry Hub | November 27, 2020 |

There is a myth in our culture that the search for meaning is some esoteric pursuit – that you have […]



Medical Pharma Biotech MedTech - Professor Kay Crossley wins top science award

Professor Kay Crossley wins top science award

Health Industry Hub | November 26, 2020 |

Medical News: World-renowned physiotherapist and La Trobe University Professor, Kay Crossley, has been awarded Victoria’s highest scientific honour, today receiving […]


News & Trends - Medical Technology

MedTech News - Growth of the surgical robotics market in Australia

Growth of the surgical robotics market in Australia

Health Industry Hub | November 25, 2020 |

In Australia, the penetration of surgical robots has been limited to a range of products that are manufactured internationally. Australia […]